Vol 14 (2023): Continuous Publishing
Case report
Published online: 2024-04-17

open access

Page views 105
Article views/downloads 60
Get Citation

Connect on Social Media

Connect on Social Media

Coexistence of chronic lymphocytic leukemia and NK/T lymphoma of the nasopharynx in a patient treated with ibrutinib

Aleksandra Rogowska1, Agnieszka Końska1, Monika Prochorec-Sobieszek23, Bożena Katarzyna Budziszewska1, Ewa Lech-Marańda1, Bartosz Puła1
Hematology in Clinical Practice 2023;14:64-68.

Abstract

Extranodal NK/T-nasal cell lymphoma is rare in Europe and North America. This report presents a case of a female chronic lymphocytic leukemia patient who developed an extranodal NK/T lymphoma of the nasopharynx shortly after the withdrawal of ibrutinib therapy.

Article available in PDF format

View PDF Download PDF file

References

  1. Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(1): 23–33.
  2. Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021; 96(12): 1679–1705.
  3. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26): 1910–1916.
  4. Jamroziak K, Puła B, Walewski J. Current treatment of chronic lymphocytic leukemia. Curr Treat Options Oncol. 2017; 18(1): 5.
  5. Puła B, Salomon-Perzyński A, Prochorec-Sobieszek M, et al. Immunochemotherapy for Richter syndrome: current insights. Immunotargets Ther. 2019; 8: 1–14.
  6. Hus I, Giannopoulos K, Jamroziak K, et al. Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021. Hematol Clin Pract. 2021; 12(2): 37–66.
  7. Pula B, Iskierka-Jazdzewska E, Dlugosz-Danecka M, et al. Long-term efficacy of ibrutinib in relapsed or refractory chronic lymphocytic leukemia: results of the polish adult leukemia study group observational study. Anticancer Res. 2020; 40(7): 4059–4066.
  8. Iskierka-Jażdżewska E, Puła B, Szeremet A, et al. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in acompassionate use program: a report from the Polish Adult Leukemia Study Group (PALG). Adv Clin Exp Med. 2019; 28(8): 1051–1057.
  9. Szmit S, Hus I, Giannopoulos K, et al. Recommendations on cardiac safety during ibrutinib therapy. Acta Haematol Pol. 2023; 54(1): 3–5.
  10. Sokołowska B, Jawniak D, Nowaczyńska A, et al. Studies on platelet function during the first year of ibrutinib treatment in patients with chronic lymphocytic leukemia. Acta Haematol Pol. 2022; 53(6): 416–420.
  11. Shen Y, Coyle L, Kerridge I, et al. Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter's syndrome. EJHaem. 2022; 3(1): 129–138.
  12. Sośnia O, Puła B. Chronic lymphocytic leukemia following venetoclax treatment failure. Acta Haematol Pol. 2022; 53(2): 94–103.
  13. Jamroziak K, Szymczyk , Hus M, et al. Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG). Eur J Haematol. 2018; 100(4): 389–391.
  14. Chi J, Park J, Saif MW. Ibrutinib-Induced vasculitis in a patient with metastatic colon cancer treated in combination with cetuximab. Case Rep Oncol Med. 2020; 2020: 6154213.
  15. Iberri DJ, Kwong BY, Stevens LA, et al. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol. 2018; 180(1): 164–166.
  16. Hammel JA, Roth GM, Ferguson N, et al. Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia. JAAD Case Rep. 2017; 3(3): 178–179.
  17. Fabbro SK, Smith SM, Dubovsky JA, et al. Panniculitis in patients undergoing treatment with the bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias. JAMA Oncol. 2015; 1(5): 684–686.
  18. Petrackova A, Turcsanyi P, Papajik T, et al. Revisiting Richter transformation in the era of novel CLL agents. Blood Rev. 2021; 49: 100824.
  19. Abi-Rafeh J, Beamish IV, Haegert DG, et al. Extranodal NK/T cell lymphoma and lymphomatoid granulomatosis in a patient with chronic lymphocytic leukaemia: Case report for a new perspective on Richter syndrome. Medicine (Baltimore). 2020; 99(19): e20106.
  20. Ge H, Wu X, Shen J, et al. A case report of extranodal NK/T-cell lymphoma in patient with chronic lymphocytic leukemia. Medicine (Baltimore). 2018; 97(30): e11619.
  21. Allen PB, Lechowicz MJo. Management of NK/T-cell lymphoma, nasal type. J Oncol Pract. 2019; 15(10): 513–520.
  22. Tse E, Zhao WL, Xiong J, et al. How we treat NK/T-cell lymphomas. J Hematol Oncol. 2022; 15(1): 74.



Hematology in Clinical Practice